Partners HealthCare income tumbles amid insurance losses
Operating income tumbled at Partners HealthCare Systems for the three months ended March 31 as insurance losses — stemming from a costly new hepatitis C drug and problems with the state's insurance website — eroded gains from its hospital business. The largest portion of the loss for Partners' health insurance unit, Neighborhood Health Plan, was about $6 million in payouts for the popular hepatitis C drug Solvaldi, which drug maker Gilead Sciences has priced at $1,000 a pill — about $84,000 for a typical course of treatment. The virus affects many low-income Medicaid patients who are served by Neighborhood Health.
- As Retail Clinics Surge, Quality Metrics MIA
- Providers' Push to Consolidate Roils Payers
- Medicare Cost, Quality Data Tools Weak, Says GAO
- RN Named Chief Patient Experience Officer
- No Employee Satisfaction, No Patient-Centered Culture
- Former NQF Co-Chair Linked to Conflicts of Interest in Journal Probe
- Population Health Pays Off for NY Collaborative
- How Simple Data Analytics is Driving Physician Incentives
- In PCMH, the 'P' is Not for 'Physician'
- AMA Pushes Lame Duck Congress for SGR Repeal